STOCK TITAN

[Form 4] USANA Health Sciences Inc Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

USANA Health Sciences (USNA) Form 4: Director John Turman Fleming reported the automatic conversion of 1,058 Restricted Stock Units (RSUs) into an equal number of common shares on 24 Jul 2025 (transaction code M – derivative conversion). No cash price was paid at conversion.

Post-transaction holdings:

  • Common stock held directly: 5,258 shares (up from 4,200).
  • Unvested RSUs remaining: 3,172 units.

The RSU award vests in four equal tranches of 25% each on 24 Jul 2025, 23 Oct 2025, 22 Jan 2026 and 23 Apr 2026. Fleming’s filing reflects the first vesting event. There was no open-market buying or selling; the transaction simply moves shares from derivative to common ownership, marginally increasing the director’s freely tradable stake.

Given the modest size relative to USNA’s ~19 million outstanding shares, the event is immaterial to corporate finances. It does, however, signal continued equity alignment between the director and shareholders.

USANA Health Sciences (USNA) Modulo 4: Il direttore John Turman Fleming ha segnalato la conversione automatica di 1.058 Unità di Azioni Vincolate (RSU) in un numero uguale di azioni ordinarie il 24 luglio 2025 (codice transazione M – conversione da derivato). Nessun prezzo in denaro è stato pagato al momento della conversione.

Detenzioni post-transazione:

  • Azioni ordinarie detenute direttamente: 5.258 azioni (in aumento rispetto a 4.200).
  • RSU non ancora maturate rimanenti: 3.172 unità.

Il premio RSU si matura in quattro tranche uguali del 25% ciascuna, rispettivamente il 24 luglio 2025, 23 ottobre 2025, 22 gennaio 2026 e 23 aprile 2026. La dichiarazione di Fleming riflette il primo evento di maturazione. Non ci sono stati acquisti o vendite sul mercato aperto; la transazione sposta semplicemente le azioni da derivato a proprietà ordinaria, aumentando marginalmente la quota liberamente negoziabile del direttore.

Considerando la dimensione modesta rispetto alle circa 19 milioni di azioni USNA in circolazione, l’evento è irrilevante per le finanze aziendali. Tuttavia, indica un continuo allineamento azionario tra il direttore e gli azionisti.

USANA Health Sciences (USNA) Formulario 4: El director John Turman Fleming reportó la conversión automática de 1,058 Unidades de Acciones Restringidas (RSU) en un número igual de acciones comunes el 24 de julio de 2025 (código de transacción M – conversión de derivado). No se pagó ningún precio en efectivo en la conversión.

Posiciones posteriores a la transacción:

  • Acciones comunes poseídas directamente: 5,258 acciones (aumentando desde 4,200).
  • RSU no adquiridas restantes: 3,172 unidades.

La concesión de RSU se consolida en cuatro tramos iguales del 25% cada uno el 24 de julio de 2025, 23 de octubre de 2025, 22 de enero de 2026 y 23 de abril de 2026. El informe de Fleming refleja el primer evento de consolidación. No hubo compra ni venta en el mercado abierto; la transacción simplemente convierte las acciones de derivado a propiedad común, aumentando ligeramente la participación libremente negociable del director.

Dada la modesta magnitud en relación con las aproximadamente 19 millones de acciones en circulación de USNA, el evento es insignificante para las finanzas corporativas. Sin embargo, señala una continua alineación accionarial entre el director y los accionistas.

USANA Health Sciences (USNA) Form 4: 이사 John Turman Fleming1,058개의 제한 주식 단위(RSU)2025년 7월 24일에 동일 수의 보통주로 자동 전환되었음을 보고했습니다 (거래 코드 M – 파생상품 전환). 전환 시 현금 가격은 지불되지 않았습니다.

거래 후 보유 현황:

  • 직접 보유한 보통주: 5,258주 (기존 4,200주에서 증가).
  • 남아있는 미확정 RSU: 3,172 단위.

RSU 수여는 2025년 7월 24일, 2025년 10월 23일, 2026년 1월 22일, 2026년 4월 23일에 각각 25%씩 네 차례에 걸쳐 확정됩니다. Fleming의 신고는 첫 번째 확정 이벤트를 반영합니다. 공개 시장에서의 매매는 없었으며, 단순히 파생상품 주식을 보통주로 전환하여 이사의 자유롭게 거래 가능한 지분을 소폭 늘렸습니다.

USNA의 약 1,900만 주 발행 주식에 비해 규모가 작아 이번 이벤트는 기업 재무에 미미한 영향을 미칩니다. 그러나 이사는 주주들과의 지속적인 지분 정렬을 보여줍니다.

USANA Health Sciences (USNA) Formulaire 4 : Le directeur John Turman Fleming a déclaré la conversion automatique de 1 058 unités d’actions restreintes (RSU) en un nombre égal d’actions ordinaires le 24 juillet 2025 (code transaction M – conversion de dérivés). Aucun prix en espèces n’a été payé lors de la conversion.

Détentions après la transaction :

  • Actions ordinaires détenues directement : 5 258 actions (en hausse par rapport à 4 200).
  • RSU non acquises restantes : 3 172 unités.

La récompense RSU se décompose en quatre tranches égales de 25 % chacune, aux dates du 24 juillet 2025, 23 octobre 2025, 22 janvier 2026 et 23 avril 2026. Le dépôt de Fleming reflète le premier événement d’acquisition. Il n’y a eu ni achat ni vente sur le marché ouvert ; la transaction se limite à transférer des actions dérivées en actions ordinaires, augmentant légèrement la part librement négociable du directeur.

Compte tenu de la taille modeste par rapport aux quelque 19 millions d’actions en circulation de USNA, l’événement est sans impact significatif sur les finances de l’entreprise. Il témoigne néanmoins d’un alignement continu des intérêts entre le directeur et les actionnaires.

USANA Health Sciences (USNA) Formular 4: Direktor John Turman Fleming meldete die automatische Umwandlung von 1.058 Restricted Stock Units (RSUs) in dieselbe Anzahl von Stammaktien am 24. Juli 2025 (Transaktionscode M – Derivateumwandlung). Beim Umtausch wurde kein Barpreis gezahlt.

Bestände nach der Transaktion:

  • Direkt gehaltene Stammaktien: 5.258 Aktien (gestiegen von 4.200).
  • Verbleibende nicht fällige RSUs: 3.172 Einheiten.

Die RSU-Zuteilung wird in vier gleichen Tranchen zu je 25 % am 24. Juli 2025, 23. Oktober 2025, 22. Januar 2026 und 23. April 2026 fällig. Flemings Meldung spiegelt das erste Fälligkeitsereignis wider. Es gab keinen Kauf oder Verkauf am offenen Markt; die Transaktion wandelt lediglich Derivate in Stammaktien um und erhöht geringfügig den frei handelbaren Anteil des Direktors.

Angesichts der vergleichsweise geringen Größe zu den etwa 19 Millionen ausstehenden USNA-Aktien ist das Ereignis unwesentlich für die Unternehmensfinanzen. Es signalisiert jedoch eine fortgesetzte Aktienausrichtung zwischen dem Direktor und den Aktionären.

Positive
  • Director increased direct share ownership by 1,058 shares, modestly aligning interests with shareholders.
Negative
  • None.

Insights

TL;DR: Routine RSU vesting—small, neutral impact.

The filing records the scheduled vesting of 1,058 RSUs by director Fleming. Such conversions (code M) are pre-arranged and do not represent discretionary insider buying. Post-event, the director’s direct ownership rises to 5,258 shares, which is still <0.03 % of shares outstanding, so influence on float or insider-sentiment screens is negligible. No shares were sold, avoiding potential negative optics. Overall governance signal: neutral to mildly positive because equity incentives remain in place.

TL;DR: Non-cash, immaterial—no valuation effect.

From a market perspective, the RSU conversion neither injects cash nor dilutes shareholders, as the shares were already counted in fully diluted share count. The 1,058 shares equal roughly $58k at a $55 share price—insignificant against USNA’s $1 bn market cap. Trading volume impact is nil. Investors can treat this as housekeeping rather than a signal of upcoming corporate developments.

USANA Health Sciences (USNA) Modulo 4: Il direttore John Turman Fleming ha segnalato la conversione automatica di 1.058 Unità di Azioni Vincolate (RSU) in un numero uguale di azioni ordinarie il 24 luglio 2025 (codice transazione M – conversione da derivato). Nessun prezzo in denaro è stato pagato al momento della conversione.

Detenzioni post-transazione:

  • Azioni ordinarie detenute direttamente: 5.258 azioni (in aumento rispetto a 4.200).
  • RSU non ancora maturate rimanenti: 3.172 unità.

Il premio RSU si matura in quattro tranche uguali del 25% ciascuna, rispettivamente il 24 luglio 2025, 23 ottobre 2025, 22 gennaio 2026 e 23 aprile 2026. La dichiarazione di Fleming riflette il primo evento di maturazione. Non ci sono stati acquisti o vendite sul mercato aperto; la transazione sposta semplicemente le azioni da derivato a proprietà ordinaria, aumentando marginalmente la quota liberamente negoziabile del direttore.

Considerando la dimensione modesta rispetto alle circa 19 milioni di azioni USNA in circolazione, l’evento è irrilevante per le finanze aziendali. Tuttavia, indica un continuo allineamento azionario tra il direttore e gli azionisti.

USANA Health Sciences (USNA) Formulario 4: El director John Turman Fleming reportó la conversión automática de 1,058 Unidades de Acciones Restringidas (RSU) en un número igual de acciones comunes el 24 de julio de 2025 (código de transacción M – conversión de derivado). No se pagó ningún precio en efectivo en la conversión.

Posiciones posteriores a la transacción:

  • Acciones comunes poseídas directamente: 5,258 acciones (aumentando desde 4,200).
  • RSU no adquiridas restantes: 3,172 unidades.

La concesión de RSU se consolida en cuatro tramos iguales del 25% cada uno el 24 de julio de 2025, 23 de octubre de 2025, 22 de enero de 2026 y 23 de abril de 2026. El informe de Fleming refleja el primer evento de consolidación. No hubo compra ni venta en el mercado abierto; la transacción simplemente convierte las acciones de derivado a propiedad común, aumentando ligeramente la participación libremente negociable del director.

Dada la modesta magnitud en relación con las aproximadamente 19 millones de acciones en circulación de USNA, el evento es insignificante para las finanzas corporativas. Sin embargo, señala una continua alineación accionarial entre el director y los accionistas.

USANA Health Sciences (USNA) Form 4: 이사 John Turman Fleming1,058개의 제한 주식 단위(RSU)2025년 7월 24일에 동일 수의 보통주로 자동 전환되었음을 보고했습니다 (거래 코드 M – 파생상품 전환). 전환 시 현금 가격은 지불되지 않았습니다.

거래 후 보유 현황:

  • 직접 보유한 보통주: 5,258주 (기존 4,200주에서 증가).
  • 남아있는 미확정 RSU: 3,172 단위.

RSU 수여는 2025년 7월 24일, 2025년 10월 23일, 2026년 1월 22일, 2026년 4월 23일에 각각 25%씩 네 차례에 걸쳐 확정됩니다. Fleming의 신고는 첫 번째 확정 이벤트를 반영합니다. 공개 시장에서의 매매는 없었으며, 단순히 파생상품 주식을 보통주로 전환하여 이사의 자유롭게 거래 가능한 지분을 소폭 늘렸습니다.

USNA의 약 1,900만 주 발행 주식에 비해 규모가 작아 이번 이벤트는 기업 재무에 미미한 영향을 미칩니다. 그러나 이사는 주주들과의 지속적인 지분 정렬을 보여줍니다.

USANA Health Sciences (USNA) Formulaire 4 : Le directeur John Turman Fleming a déclaré la conversion automatique de 1 058 unités d’actions restreintes (RSU) en un nombre égal d’actions ordinaires le 24 juillet 2025 (code transaction M – conversion de dérivés). Aucun prix en espèces n’a été payé lors de la conversion.

Détentions après la transaction :

  • Actions ordinaires détenues directement : 5 258 actions (en hausse par rapport à 4 200).
  • RSU non acquises restantes : 3 172 unités.

La récompense RSU se décompose en quatre tranches égales de 25 % chacune, aux dates du 24 juillet 2025, 23 octobre 2025, 22 janvier 2026 et 23 avril 2026. Le dépôt de Fleming reflète le premier événement d’acquisition. Il n’y a eu ni achat ni vente sur le marché ouvert ; la transaction se limite à transférer des actions dérivées en actions ordinaires, augmentant légèrement la part librement négociable du directeur.

Compte tenu de la taille modeste par rapport aux quelque 19 millions d’actions en circulation de USNA, l’événement est sans impact significatif sur les finances de l’entreprise. Il témoigne néanmoins d’un alignement continu des intérêts entre le directeur et les actionnaires.

USANA Health Sciences (USNA) Formular 4: Direktor John Turman Fleming meldete die automatische Umwandlung von 1.058 Restricted Stock Units (RSUs) in dieselbe Anzahl von Stammaktien am 24. Juli 2025 (Transaktionscode M – Derivateumwandlung). Beim Umtausch wurde kein Barpreis gezahlt.

Bestände nach der Transaktion:

  • Direkt gehaltene Stammaktien: 5.258 Aktien (gestiegen von 4.200).
  • Verbleibende nicht fällige RSUs: 3.172 Einheiten.

Die RSU-Zuteilung wird in vier gleichen Tranchen zu je 25 % am 24. Juli 2025, 23. Oktober 2025, 22. Januar 2026 und 23. April 2026 fällig. Flemings Meldung spiegelt das erste Fälligkeitsereignis wider. Es gab keinen Kauf oder Verkauf am offenen Markt; die Transaktion wandelt lediglich Derivate in Stammaktien um und erhöht geringfügig den frei handelbaren Anteil des Direktors.

Angesichts der vergleichsweise geringen Größe zu den etwa 19 Millionen ausstehenden USNA-Aktien ist das Ereignis unwesentlich für die Unternehmensfinanzen. Es signalisiert jedoch eine fortgesetzte Aktienausrichtung zwischen dem Direktor und den Aktionären.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Fleming John Turman

(Last) (First) (Middle)
3838 WEST PARKWAY BLVD.

(Street)
SALT LAKE CITY UT 84120

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
USANA HEALTH SCIENCES INC [ USNA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/24/2025 M 1,058 A (1) 5,258 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 07/24/2025 M 1,058 (2) (2) Common Stock 1,058 $0 3,172 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of USNA common stock.
2. Restricted Stock Units vest 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
Remarks:
/s/ Joshua Foukas, Attorney-in-Fact 07/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did USNA director John Fleming report in the 24 Jul 2025 Form 4?

He converted 1,058 RSUs into common stock, raising his direct holding to 5,258 shares.

Was the transaction an open-market purchase or sale?

No. It was a code M derivative conversion, part of scheduled RSU vesting.

How many USANA RSUs does Fleming still hold after the transaction?

He retains 3,172 unvested RSUs that will vest through April 2026.

Does the Form 4 filing affect USNA’s share count or earnings?

No. The shares were already included in diluted share count; no cash or earnings impact occurs.

Is this insider activity considered bullish for USNA stock?

Because it is an automatic vesting, the signal is neutral; no discretionary buying took place.
Usana Health Sciences Inc

NYSE:USNA

USNA Rankings

USNA Latest News

USNA Latest SEC Filings

USNA Stock Data

549.75M
10.76M
42.19%
59.03%
4.45%
Packaged Foods
Medicinal Chemicals & Botanical Products
Link
United States
SALT LAKE CITY